NASDAQ:MEIP - MEI Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 321.46 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.61
▼ -0.16 (-5.78%)

This chart shows the closing price for MEIP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MEI Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEIP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEIP

Analyst Price Target is $11.00
▲ +321.46% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for MEI Pharma in the last 3 months. The average price target is $11.00, with a high forecast of $20.00 and a low forecast of $8.00. The average price target represents a 321.46% upside from the last price of $2.61.

This chart shows the closing price for MEIP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in MEI Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2021Truist SecuritiesLower Price TargetBuy$12.00 ➝ $8.00High
9/9/2021TruistLower Price TargetBuy$12.00 ➝ $8.00High
9/7/2021RoweBoost Price TargetPositive ➝ Buy$11.50 ➝ $20.00High
9/5/2021BTIG ResearchReiterated RatingBuy$9.00Medium
9/3/2021HC WainwrightReiterated RatingBuy$10.00Medium
6/13/2021BTIG ResearchReiterated RatingBuy$5.50Medium
2/8/2021HC WainwrightReiterated RatingBuy$10.00High
10/21/2020Lifesci CapitalReiterated RatingOutperformMedium
10/12/2020Brookline Capital ManagementReiterated RatingBuyMedium
9/22/2020Alliance Global PartnersInitiated CoverageBuy$9.00Medium
7/6/2020SunTrust BanksLower Price Target$16.00 ➝ $12.00High
7/5/2020Ci CapitalReiterated RatingBuy$9.00High
6/22/2020Ci CapitalReiterated RatingBuy$9.00High
6/14/2020Wells Fargo & CompanyReiterated RatingOverweight ➝ Market Perform$13.00High
5/29/2020SunTrust BanksInitiated CoverageBuy$16.00High
4/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$11.00 ➝ $13.00High
2/10/2020HC WainwrightReiterated RatingBuy$10.00Low
6/24/2019HC WainwrightReiterated RatingBuy$10.00Low
6/7/2019HC WainwrightReiterated RatingBuy$10.00Low
5/10/2019HC WainwrightReiterated RatingBuyHigh
3/19/2019OppenheimerReiterated RatingBuyMedium
2/12/2019BTIG ResearchInitiated CoverageBuyHigh
12/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$10.00High
7/26/2018Stifel NicolausUpgradeHold ➝ Buy$7.00High
7/13/2018SunTrust BanksInitiated CoverageBuy$12.00Medium
6/6/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
4/12/2018LaidlawInitiated CoverageBuy$7.00High
1/8/2018OppenheimerSet Price TargetBuy$7.00Low
12/21/2017OppenheimerSet Price TargetBuy$7.00Medium
12/11/2017OppenheimerReiterated RatingBuy$6.50High
6/14/2017OppenheimerSet Price TargetBuy$7.00Low
5/31/2017OppenheimerSet Price TargetBuy$7.00High
5/25/2017OppenheimerInitiated CoverageOutperform$6.00 ➝ $6.50High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
MEI Pharma logo
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $2.61
Low: $2.58
High: $2.73

50 Day Range

MA: $2.89
Low: $2.61
High: $3.23

52 Week Range

Now: $2.61
Low: $2.40
High: $4.57

Volume

440,816 shs

Average Volume

647,657 shs

Market Capitalization

$294.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of MEI Pharma?

The following Wall Street sell-side analysts have issued reports on MEI Pharma in the last twelve months: BTIG Research, HC Wainwright, Rowe, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for MEIP.

What is the current price target for MEI Pharma?

5 Wall Street analysts have set twelve-month price targets for MEI Pharma in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 321.5%. Rowe has the highest price target set, predicting MEIP will reach $20.00 in the next twelve months. Truist has the lowest price target set, forecasting a price of $8.00 for MEI Pharma in the next year.
View the latest price targets for MEIP.

What is the current consensus analyst rating for MEI Pharma?

MEI Pharma currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MEIP will outperform the market and that investors should add to their positions of MEI Pharma.
View the latest ratings for MEIP.

How do I contact MEI Pharma's investor relations team?

MEI Pharma's physical mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company's listed phone number is (858) 369-7100 and its investor relations email address is [email protected] The official website for MEI Pharma is www.meipharma.com.